CSIMarket
 
Embecta Corp   (EMBC)
Other Ticker:  
 
 
Price: $14.4800 $-0.30 -2.030%
Day's High: $14.72 Week Perf: -3.27 %
Day's Low: $ 14.33 30 Day Perf: -14.92 %
Volume (M): 452 52 Wk High: $ 33.07
Volume (M$): $ 6,546 52 Wk Avg: $21.35
Open: $14.66 52 Wk Low: $12.72



 Market Capitalization (Millions $) 832
 Shares Outstanding (Millions) 57
 Employees -
 Revenues (TTM) (Millions $) 1,121
 Net Income (TTM) (Millions $) 55
 Cash Flow (TTM) (Millions $) -87
 Capital Exp. (TTM) (Millions $) 25

Embecta Corp
The company is a global medical device company that focuses on providing solutions to improve the health and well-being of people living with diabetes. Their products are used by nearly 30 million people in over 100 countries for insulin administration and to aid with the daily management of diabetes. The company has a broad portfolio of marketed products, including a variety of pen needles, syringes, and safety injection devices. The company also seeks to promote advances in diabetes care through thought leadership and engagement with the diabetes community. They have three manufacturing sites located in Ireland, the United States, and China, and they distribute their products through a variety of channels, including retail, hospitals, pharmacies, and other institutional channels. The company uses a combination of patents, copyrights, trademarks, trade secrets, nondisclosure agreements, and other measures to establish and protect their proprietary rights.

In summary, the company is a leading global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. With close to 100 years of experience in the industry, the company has become one of the most widely recognized and respected brands in diabetes management in the world.
The company's broad portfolio of products, including pen needles, syringes, and safety injection devices, as well as its proprietary digital application designed to assist people with managing their diabetes, has made a significant impact in diabetes care. The company's commitment to research and development, coupled with its global operations and strong financial performance, positions it for continued growth and success in the future.


   Company Address: 300 Kimball Drive, Suite 300 Parsippany 7054 NJ
   Company Phone Number: 401-0000   Stock Exchange / Ticker: NASDAQ EMBC
    Next quarterly dividend pay out on March 15, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Dividend

Embecta Corp Sets New Record with Quarterly Cash Dividend Announcement

Published Fri, Feb 9 2024 11:00 AM UTC

Embecta Corp Announces Record Quarterly Cash Dividend: A Look at the Company's Dividend Pay Out Ratio On February 9, 2024, Embecta Corp (Nasdaq: EMBC) made an exciting announcement regarding their quarterly cash dividend. The Board of Directors declared a dividend of $0.15 for each issued and outstanding share of the company's common stock, payable on March 15, 2024, to s...

Embecta Corp

Embecta Corp Announces Decent Performance, but Income Decline Overshadows Revenue Increase

As a financial analyst for the , I have been closely following the recent financial results of Embecta Corp (Nasdaq: EMBC). The company reported a revenue advance of 0.435% in the most recent fiscal period, reaching $276.90 million, but this was overshadowed by a significant income decline of -42.62% compared to the same period a year prior, with EPS at $0.35.
It is important to note that while Embecta Corp saw an increase in revenue, it fell below the industry average, which experienced a 3.48% growth. The company also experienced a decrease in revenue from the prior reporting period, dropping by -1.669% to $281.60 million, while EPS saw a significant increase of 235.65% from $0.10 per share.

Embecta Corp

Embecta Corp Faces Significant Decline in Revenue During Fourth Quarter of 2023

Financial News Report:
Embecta Corp (NASDAQ: EMBC), a global diabetes care company, has reported a significant decline in income and profit for the July to September 2023 period. The company's income fell sharply by -92.65% to $0.10 per share compared to $1.42 per share in the same period last year. Additionally, profit plummeted by -59.89% from $0.26 per share in the prior quarter.
The revenue of Embecta Corp also went down sharply by -50.062% to $281.60 million from $563.90 million in the corresponding quarter a year prior. This is a sequential decrease of -1.366% from $285.50 million. In comparison, the rest of the Medical Equipment & Supplies sector posted a top-line growth in the fourth quarter of 2023.

Dividend

Embecta Corp. Empowers Shareholders with Quarterly Cash Dividend, Showcasing Strong Financial Performance

Published Tue, Nov 21 2023 10:00 AM UTC

Embecta Corp. Declares Quarterly Cash Dividend: An Encouraging Move for Shareholders
PARSIPPANY, N.J., Nov. 21, 2023 - Embecta Corp. (Nasdaq: EMBC), a leading player in the technology industry, has announced its decision to declare a quarterly cash dividend of $0.15 for each issued and outstanding share of the company's common stock. The dividend payment provides a welco...

Embecta Corp

Embecta Corp Reports Decrease of -1.924% in Third Quarter 2023 Revenue, But Stock Performs Strongly Amidst Challenges



Embecta Corp, a prominent player in the Medical Equipment & Supplies industry, recently reported a decline in earnings and revenue for the third quarter of 2023. However, in the face of these challenges, the company's stock has recorded significant gains in the past year, indicating a potential bullish outlook. This article delves into the company's financial performance, the factors impacting its stock, and the potential for future growth.
Financial Performance:
In the third quarter of 2023, Embecta Corp witnessed a substantial reduction in earnings per share by -75.7% to $0.26 compared to the previous year, while revenue decreased by -1.924% to $285.50 million. These figures indicate a challenging period for the company. Despite this, when compared to the industry's average, Embecta Corp's performance may seem contradictory.






 

Embecta's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com